Keyphrases
Finland
89%
Three-dimensional (3D)
64%
Laparoscopic Radical Prostatectomy
50%
Penile Cancer
50%
Prostate Cancer
50%
Postoperative Complications
39%
Instillation Therapy
33%
Visual Analog Scale
33%
Robot-assisted Laparoscopic Radical Prostatectomy
33%
Robot-assisted
33%
Patient Characteristics
33%
Men's Experiences
33%
Laparoscopic Prostatectomy
33%
Expanded Prostate Cancer Index Composite
30%
Surgical Patients
27%
After Surgery
27%
Finnish Population
26%
Prostate
26%
Functional Outcome
25%
Confidence Interval
24%
Randomized Controlled Trial
24%
Bladder Cancer
22%
Prostate Cancer Risk
21%
Androgen Deprivation Therapy
21%
Continence
19%
Informational Needs
18%
Incidence Rate
18%
Meta-analysis of Randomized Controlled Trials
16%
Southwest Oncology Group
16%
Group Communication Protocol
16%
12-month Outcomes
16%
Robot-assisted Radical Prostatectomy
16%
Prostate Cancer Survival
16%
Metastasis
16%
Prospective Observational Study
16%
Multi-sampling
16%
Origin Tracing
16%
Perceived Quality
16%
Maintenance Therapy
16%
Repetitive Transcranial Magnetic Stimulation (rTMS)
16%
Hyperuricemia
16%
Chronic Pelvic Pain Syndrome
16%
Chronic Prostatitis Symptom Index
16%
Chronic Prostatitis
16%
Clinically Significant Prostate Cancer
16%
Shared Decision Making
16%
Population-based Cohort
16%
Late Infection
16%
Genome Analysis
16%
Familial Aggregation
16%
Medicine and Dentistry
Prostatectomy
100%
Prostate Cancer
93%
Robot-Assisted Prostatectomy
52%
Randomized Controlled Trial
50%
Continence
40%
Malignant Neoplasm
39%
Postoperative Complication
33%
Infection
33%
Visual Analog Scale
33%
Urinary System
28%
Surgery
19%
Symptom
18%
Cancer Mortality
18%
Cross Sectional Study
18%
Surgical Anastomosis
16%
Magnetic Resonance Imaging
16%
Genome Analysis
16%
Maintenance Therapy
16%
Bacilli
16%
Hyperuricemia
16%
Systematic Review
16%
Shared Decision Making
16%
Repetitive Transcranial Magnetic Stimulation
16%
Chronic Pelvic Pain Syndrome
16%
Chronic Prostatitis
16%
Non Muscle Invasive Bladder Cancer
16%
Erectile Dysfunction
16%
Cohort Analysis
16%
Cancer Incidence
16%
Penile Cancer
16%
Testis Cancer
16%
Personalized Medicine
16%
Cancer Surgery
16%
Meta-Analysis
16%
Phallus
16%
Luteinizing Hormone Receptor
16%
Oncology
16%
Risk Evaluation
16%
Urine Incontinence
15%
Metastatic Carcinoma
14%
Incontinence
12%
Surgical Margin
12%
Prostate Specific Antigen
10%
Biopsy
9%
Fisher Exact Test
9%
Biochemical Recurrence
9%
Bladder Cancer
8%
Perceived Quality of Care
8%
Orthopedic Surgery
8%
General Surgery
8%
